SE502324C2 - Administreringssystem för farmakologiskt aktiva medel som är inkapslade i skyddande proteinoidmikrosfärer - Google Patents

Administreringssystem för farmakologiskt aktiva medel som är inkapslade i skyddande proteinoidmikrosfärer

Info

Publication number
SE502324C2
SE502324C2 SE8900542A SE8900542A SE502324C2 SE 502324 C2 SE502324 C2 SE 502324C2 SE 8900542 A SE8900542 A SE 8900542A SE 8900542 A SE8900542 A SE 8900542A SE 502324 C2 SE502324 C2 SE 502324C2
Authority
SE
Sweden
Prior art keywords
microspheres
agent
insulin
composition according
stable
Prior art date
Application number
SE8900542A
Other languages
English (en)
Swedish (sv)
Other versions
SE8900542D0 (sv
SE8900542L (sv
Inventor
Solomon S Steiner
Robert Rosen
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of SE8900542D0 publication Critical patent/SE8900542D0/xx
Publication of SE8900542L publication Critical patent/SE8900542L/
Publication of SE502324C2 publication Critical patent/SE502324C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8900542A 1986-08-18 1989-02-16 Administreringssystem för farmakologiskt aktiva medel som är inkapslade i skyddande proteinoidmikrosfärer SE502324C2 (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89736186A 1986-08-18 1986-08-18
PCT/US1987/002025 WO1988001213A1 (fr) 1986-08-18 1987-08-14 Systemes de distribution pour agents pharmacologiques
CA000554255A CA1323305C (fr) 1986-08-18 1987-12-14 Systeme de delivrance d'agents pharmaceutiques

Publications (3)

Publication Number Publication Date
SE8900542D0 SE8900542D0 (sv) 1989-02-16
SE8900542L SE8900542L (sv) 1989-02-16
SE502324C2 true SE502324C2 (sv) 1995-10-02

Family

ID=25671632

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8900542A SE502324C2 (sv) 1986-08-18 1989-02-16 Administreringssystem för farmakologiskt aktiva medel som är inkapslade i skyddande proteinoidmikrosfärer

Country Status (11)

Country Link
US (1) US4925673A (fr)
EP (2) EP0318512B1 (fr)
JP (1) JP2876058B2 (fr)
AU (1) AU610083B2 (fr)
CA (1) CA1323305C (fr)
CH (1) CH671155A5 (fr)
GB (1) GB2217201B (fr)
NL (1) NL8720442A (fr)
NO (1) NO178055C (fr)
SE (1) SE502324C2 (fr)
WO (1) WO1988001213A1 (fr)

Families Citing this family (460)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GR1000047B (el) * 1988-02-04 1990-05-11 Clinical Technologies Ass Συστηματα χορηγησης φαρμακολογικων παραγοντων.
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
CA2018064C (fr) * 1989-06-08 1996-04-16 Kaspar Saner Transducteur de force et methode de fabrication de ce transducteur
CA2071867A1 (fr) * 1989-11-06 1991-05-07 Edith Mathiowitz Mode de fabrication de microspheres proteiniques
ATE224911T1 (de) 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US6344213B1 (en) * 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
EP0656904A1 (fr) * 1992-05-28 1995-06-14 Centocor Inc. Peptides inhibiteurs de la liaison de selectine
JPH08504171A (ja) * 1992-05-28 1996-05-07 セントコー・インコーポレーテッド セレクチン結合のペプチド阻害剤
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
WO1994005314A1 (fr) * 1992-09-08 1994-03-17 Centocor, Inc. Inhibiteurs peptidiques de l'adhesion des leucocytes
JPH08503694A (ja) * 1992-09-08 1996-04-23 セントコー・インコーポレーテッド ペプチド系の細胞接着阻害物質
WO1994007367A1 (fr) * 1992-09-29 1994-04-14 Apollon, Inc. Oligomeres antiviraux liant des voies de polypurine d'arn monocatenaire ou d'hybrides d'arn-adn
WO1994010980A1 (fr) * 1992-11-16 1994-05-26 Corporation Of Mercer University Compositions comprenant des anticorps de neutralisation microencapsules
WO1994014836A1 (fr) * 1992-12-18 1994-07-07 Centocor, Inc. Inhibiteurs peptidiques de liaison de selectine
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6461643B2 (en) * 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
JP4361601B2 (ja) * 1993-04-22 2009-11-11 エミスフェアー・テクノロジーズ・インク 経口薬剤移送組成物およびその方法
WO1994028878A1 (fr) * 1993-06-14 1994-12-22 Emisphere Technologies, Inc. Excipients proteinoidiques
WO1995014787A1 (fr) * 1993-11-22 1995-06-01 Centocor, Inc. Peptides inhibiteurs de liaison a la selectine
CA2184242C (fr) * 1994-02-28 2000-05-02 Jorg Kreuter Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
JPH10503364A (ja) * 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
US7078511B1 (en) 1994-06-23 2006-07-18 Massachusette Institute Of Technology Class BI and CI scavenger receptors
US5962322A (en) * 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US6051258A (en) * 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US5824345A (en) * 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5667806A (en) * 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US6084112A (en) * 1995-09-11 2000-07-04 Emisphere Technologies, Inc. Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones
AU717113B2 (en) 1995-11-09 2000-03-16 Health Protection Agency Microencapsulated DNA for vaccination and gene therapy
US5843884A (en) * 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US5888982A (en) * 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
JP2000512671A (ja) 1996-06-14 2000-09-26 エミスフェアー テクノロジーズ インク マイクロカプセル化香料及び調製方法
US6004749A (en) * 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US6107029A (en) * 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US5859227A (en) * 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins
EP0942967A1 (fr) 1996-11-06 1999-09-22 Children's Medical Center Corporation Animal transgenique exprimant un syndecan dans les regions de l'hypothalamus
CA2270160A1 (fr) 1996-11-08 1998-05-14 Oklahoma Medical Research Foundation Expression specifique de l'endothelium regulee par des elements regulateurs du recepteur epcr
WO1998021951A1 (fr) 1996-11-18 1998-05-28 Emisphere Technologies, Inc. Procede et composition pour induire une tolerance orale chez les mammiferes
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
EP1015008B1 (fr) 1997-02-07 2015-08-05 Emisphere Technologies, Inc. Composes et compositions destines a l'administration d'agents actifs
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
EP1007091A1 (fr) * 1997-09-05 2000-06-14 Massachusetts Institute Of Technology Antagoniste de sr-bi et son utilisation comme contraceptif et pour le traitement de la surproduction de steroides
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US6858706B2 (en) 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US6448224B1 (en) 1998-05-06 2002-09-10 St. Jude Children's Research Hospital Antibiotics and methods of using the same
US6331407B1 (en) 1998-05-06 2001-12-18 St. Jude Children's Research Hospital Antibiotics and methods of using the same
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
EP1100522B1 (fr) 1998-07-27 2016-12-07 Emisphere Technologies, Inc. Administration de substances actives par la voie pulmonaire
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ509410A (en) 1998-08-07 2003-08-29 Emisphere Tech Inc Compounds and compositions for delivering active agents
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US6921825B2 (en) 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
DE19848002A1 (de) 1998-10-17 2000-04-20 Goldschmidt Ag Th Polypeptid-Polysiloxan-Copolymere
AU773891C (en) * 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US6773911B1 (en) * 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
IL143962A0 (en) 1999-01-08 2002-04-21 Emisphere Tech Inc Polymeric delivery agents and delivery agent compounds
MXPA01008611A (es) 1999-02-26 2003-06-24 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU5269800A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in allergy cells
US6485706B1 (en) 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US7361684B2 (en) * 1999-06-28 2008-04-22 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6908900B2 (en) * 2001-01-17 2005-06-21 Zimmer & Associates Ag Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
US20030060413A1 (en) * 2001-09-06 2003-03-27 Zimmer Robert H. Derivatives of pseudo-peptides, their preparation and their biological uses
US7671029B2 (en) 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
CA2349406C (fr) * 1999-09-03 2011-01-11 Amgen Inc. Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
EP1231905B1 (fr) 1999-11-15 2009-04-08 BioCure, Inc. Particules polymeres creuses sensibles
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
CA3016482A1 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
CA2407083A1 (fr) 2000-04-21 2001-11-01 Amgen Inc. Derive de peptides apo-ai/aii
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
FR2814952B1 (fr) 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20030225300A1 (en) * 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
MXPA03010210A (es) 2001-05-11 2004-03-10 Amgen Inc Peptidos y moleculas relacionadas que se enlazan a tall-1.
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
DE60232733D1 (de) * 2001-08-30 2009-08-06 Sinai School Medicine Alternativ gesplicter zirkulierender gewebefaktor
ES2429132T3 (es) 2001-08-31 2013-11-13 The Rockefeller University Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
ES2624547T3 (es) 2001-11-14 2017-07-14 Janssen Biotech, Inc. Anticuerpos anti il 6, composiciones, métodos y usos
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) * 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
EP2963017A1 (fr) 2002-03-11 2016-01-06 Molecular Insight Pharmaceuticals, Inc. Complexes technetium-dipyridine et leurs procedes d'utilisation
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
AU2003252075A1 (en) * 2002-07-16 2004-02-02 University Of South Florida Human immunosuppressive protein
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
JP2006515274A (ja) * 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (fr) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Nanostructures de peptides encapsulant une matiere etrangere ainsi que procede de fabrication correspondant
CA2515583C (fr) 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, acides nucleiques les codant, et procedes de fabrication et d'utilisation correspondants
EP1610820B2 (fr) 2003-04-04 2013-08-21 Genentech, Inc. Preparations d'anticorps et de proteines a forte concentration
WO2004094457A2 (fr) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Composition peptidomimetique rgd stable
CA2525184C (fr) 2003-05-09 2012-10-30 Centocor, Inc. Proteines derivees de l'immunoglobine specifiques de il-23p40, compositions, procedes et utilisations
CN1849141A (zh) 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
KR20060028675A (ko) 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
WO2005007812A2 (fr) 2003-07-03 2005-01-27 University Of Medicine And Dentistry Of New Jersey Genes utiles en tant qu'outils de diagnostic pour l'autisme
WO2005016349A1 (fr) * 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de l'accumulation des leucocytes
WO2005016348A1 (fr) * 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
AU2004267044B8 (en) * 2003-08-20 2009-12-17 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon like peptide (GLP)-1 compound or an melanocortin 4 receptor (MC4) agonist peptide
CA2532026C (fr) 2003-08-20 2012-04-17 Eli Lilly And Company Composes, procedes et preparations destines a l'apport oral d'un compose peptidique de type glucagon (glp-1) ou d'un peptide agoniste du recepteur 4 de melanocortine (mc4)
US20050233435A1 (en) * 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
AU2004273986B2 (en) 2003-09-15 2010-04-22 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use in angiogenesis
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
JP4917889B2 (ja) * 2003-09-25 2012-04-18 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を処置するための組成物及びその使用方法
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
EP3279328A1 (fr) 2003-11-14 2018-02-07 Children's Medical Center Corporation Ribozymes à autoclivage et utilisations correspondantes
EP1709084A4 (fr) 2003-12-23 2008-05-28 Nono Inc Polypeptides pour la modulation de la liaison des proteines du canal de recepteur de potentiel transitoire et proteines associees au recepteur de potentiel transitoire
ATE433746T1 (de) * 2004-03-12 2009-07-15 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
EP1733056B1 (fr) 2004-03-31 2013-05-22 The General Hospital Corporation Procede permettant de determiner la reponse d'un cancer a des traitements cibles par le recepteur du facteur de croissance epidermique
US7252446B2 (en) * 2004-03-31 2007-08-07 Brother Kogoy Kabushiki Kaisha Image forming apparatus
WO2005098008A1 (fr) * 2004-04-05 2005-10-20 Massachusetts Institute Of Technology Modele murin de crise cardiaque inductible par regime lipidique
ES2605792T3 (es) * 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
EP1755609A1 (fr) * 2004-05-25 2007-02-28 Icos Corporation Methodes de traitement et/ou de prevention de la proliferation aberrante des cellules hematopoietiques
JP5209302B2 (ja) 2004-06-15 2013-06-12 ポリメディックス、インク． ポリカチオン化合物とその使用
EP1773400A2 (fr) * 2004-07-08 2007-04-18 Amgen Inc. Peptides therapeutiques
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (fr) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles de nanostructures a base de peptides et leur procede de formation
WO2006018850A2 (fr) 2004-08-19 2006-02-23 Tel Aviv University Future Technology Development L.P. Compositions et leurs methodes d'utilisation dans le traitement de maladies associees aux amyloides
EP1786784B1 (fr) 2004-08-20 2010-10-27 MannKind Corporation Catalyse de la synthese de dicetopiperazine
CA2578175C (fr) 2004-08-23 2014-10-14 Mannkind Corporation Sels de dicetopiperazine, sels de dicetomorpholine ou sels de dicetodioxane permettant l'administration de medicaments
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
CA2580796C (fr) * 2004-09-24 2013-03-26 Amgen Inc. Molecules fc modifiees ayant des peptides inserees dans les regions de boucle interne
CN1296098C (zh) * 2004-09-29 2007-01-24 薛南荣 口服胰岛素保护剂
AU2005295038B2 (en) 2004-10-06 2012-05-17 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP1812473A4 (fr) 2004-11-16 2009-12-23 Univ Boston Role du recepteur dear dans l'hypertension et l'angiogenese
EP2042186A1 (fr) 2005-01-31 2009-04-01 Vaxinnate Corporation Nouveaux polypeptides se fixant au récepteur 2 (TLR2) de type Toll
AU2006214190A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CA2981431C (fr) 2005-06-08 2021-04-13 Dana-Farber Cancer Institute Inc. Utilisation de composes qui reduisent l'activite ou l'expression de la mort cellulaire programmee 1 pour le traitement des lymphomes
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7803404B2 (en) 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) * 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
WO2007043048A2 (fr) * 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Hydrogels auto-assembles et leurs procedes d'elaboration et d'utilisation
TW200732350A (en) * 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007082144A2 (fr) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine
US20070208074A1 (en) * 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
EP2216403A3 (fr) 2006-02-02 2010-11-24 Verenium Corporation Estérases et acides nucléiques associés et procédés
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
US7786090B2 (en) * 2006-03-01 2010-08-31 President And Fellows Of Harvard College Methods and compositions for treating and preventing neurologic disorders
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
WO2007124361A2 (fr) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research B7-h1 soluble
ES2530716T3 (es) 2006-04-21 2015-03-04 Intervet Int Bv Especies de pestivirus
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
WO2007137163A2 (fr) * 2006-05-19 2007-11-29 Georgia Tech Research Corporation Ligand des transporteurs abc
US20080242608A1 (en) * 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US7960606B2 (en) * 2006-06-20 2011-06-14 The J. David Gladstone Institutes Mouse model of chronic heart failure and coronary atherosclerosis regression
EP2037928B1 (fr) 2006-06-26 2012-01-11 Amgen Inc. Procédés de traitement de l'athérosclérose
WO2008008472A2 (fr) * 2006-07-13 2008-01-17 President And Fellows Of Harvard College Méthodes et compositions pour moduler une formation de synapses
US8324158B2 (en) * 2006-07-14 2012-12-04 Georgia Tech Research Corporation Methods for inhibiting CLC-2 channel with GATX2
US7825093B2 (en) 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
US20100234417A1 (en) * 2006-11-10 2010-09-16 Dimerix Bioscience Pty Ltd. Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
CA2669399A1 (fr) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones destinees au traitement de troubles inflammatoires et de cancers
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
JP2010513526A (ja) * 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
WO2008083169A2 (fr) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions et procédés pour le traitement de troubles immunologiques
EP2586458B1 (fr) * 2006-12-27 2016-08-24 The Johns Hopkins University Compositions et procédés pour le traitement d'inflammations et de maladies auto-immunes
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
EP2133365B1 (fr) 2006-12-27 2017-05-17 Emory University Compositions et procédés pour le traitement d'infections et de tumeurs
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US8389482B2 (en) 2007-01-30 2013-03-05 New York University Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
CA2687141C (fr) 2007-05-22 2014-04-01 Amgen Inc. Compositions et procedes pour produire des proteines de fusion bioactives
WO2008148023A2 (fr) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions et procédés pour traiter des troubles neurologiques
WO2009029342A2 (fr) * 2007-07-13 2009-03-05 The Johns Hopkins University Variants de b7-dc
DK2181190T3 (da) 2007-07-26 2014-03-31 Amgen Inc Modificerede lecithin-kolesterol-acyltransferase-enzymer
JP2010539089A (ja) * 2007-09-07 2010-12-16 ゲンシア コーポレーション ミトコンドリア組成物及びその使用
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
WO2009058997A2 (fr) * 2007-11-01 2009-05-07 Biocept Inc. Isolement non invasif d'acide nucléique fœtal
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
EP2240171B1 (fr) * 2008-01-09 2014-08-13 Molecular Insight Pharmaceuticals, Inc. Inhibiteurs de l'anhydrase IX
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
CN105363034A (zh) * 2008-05-23 2016-03-02 香港大学 治疗流感的联合疗法
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2570147B1 (fr) 2008-06-13 2017-10-18 MannKind Corporation Inhalateur de poudre sèche et système d'administration de médicament
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US20100008900A1 (en) * 2008-07-14 2010-01-14 The University Of Hong Kong Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
CA2734225A1 (fr) 2008-08-15 2010-02-18 Georgetown University Regulateurs fluorescents de l'expression de rassf1a et de la proliferation de cellules cancereuses humaines
JP5656834B2 (ja) 2008-08-22 2015-01-21 サノフイ 肥満細胞トリプターゼインヒビターとしての［４−（５−アミノメチル−２−フルオロ−フェニル）−ピペリジン−１−イル］−［７−フルオロ−１−（２−メトキシ−エチル）−４−トリフルオロメトキシ−１ｈ−インドール−３−イル］−メタノン
CN102203125A (zh) * 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) * 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
CN105330603A (zh) * 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
EP2342217B1 (fr) * 2008-10-21 2015-12-23 International Vaccine Institute Nouveaux antigènes de protéines de shigella et méthodes
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
EP2389361B1 (fr) * 2008-12-05 2016-08-24 Molecular Insight Pharmaceuticals, Inc. Complexes de technétium et de rhénium bis (hétéroaryle) et procédés d'utilisation de ceux-ci pour inhiber le psma
WO2010065906A2 (fr) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Produits radiopharmaceutiques spécifiques de ca-ix pour le traitement et l'imagerie de cancer
WO2010065899A2 (fr) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Complexes de technétium- et rhénium-bis (hétéroaryles) et leurs procédés d'utilisation
WO2010068680A1 (fr) 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Adjuvants spécifiques du lignage 17 du type lymphocytes t, compositions et méthodes
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2010075332A1 (fr) 2008-12-23 2010-07-01 Charitable Leadership Foundation Ligands à petites molécules du site de reconnaissance rgd de l'intégrine et méthodes d'utilisation
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2010120506A1 (fr) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Polythérapie anticancéreuse par cétuximab et tétrac
EA201101507A1 (ru) * 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
KR20180079458A (ko) 2009-06-12 2018-07-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
CA2765792C (fr) 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Formulations nanoparticulaires et polymeres pour hormone thyroidienne, analogues, antagonistes et formulations et utilisations de celles-ci
EP2456443A1 (fr) 2009-07-21 2012-05-30 Gilead Calistoga LLC Traitement de troubles du foie par des inhibiteurs de pi3k
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
WO2011049625A1 (fr) 2009-10-20 2011-04-28 Mansour Samadpour Procédé de criblage d'aflatoxine dans des produits
WO2011053468A1 (fr) 2009-10-30 2011-05-05 Sanofi-Aventis Dérivés de l'acide aminobenzoïque destinés à être utilisés dans le traitement de troubles associés à la déshydrogénase
EP2496295A1 (fr) 2009-11-03 2012-09-12 MannKind Corporation Appareil et méthode de simulation d'efforts d'inhalation
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
US20120316187A1 (en) 2009-11-13 2012-12-13 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
ES2533536T3 (es) 2009-11-19 2015-04-10 Solis Biodyne Oü Composiciones para aumentar la estabilidad y actividad de polipéptidos, y métodos relacionados
CA2785439A1 (fr) 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones et leur synthese
KR20120106824A (ko) 2009-12-23 2012-09-26 사노피 ［4［4?（5?아미노메틸?2?플루오로-페닐）?피페리딘?1?일］?（1ｈ?피롤로?피리딘?일）?메탄온들의 전구약물들 및 이들의 합성
EP2528938A4 (fr) 2010-01-27 2013-10-23 Childrens Medical Center Fragments proangiogènes de prominine 1 et utilisations de ceux-ci
CA2792125C (fr) 2010-03-22 2019-02-12 Genentech, Inc. Compositions et procedes utiles pour stabiliser les formulations contenant des proteines
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
CN103068824B (zh) 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
WO2012018387A2 (fr) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions et méthodes de recherche de mutations causales dans des troubles génétiques
WO2012048002A1 (fr) 2010-10-07 2012-04-12 Biodel Inc. Assemblage automatique de tripeptides pour stabiliser des biomolécules
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2468883A1 (fr) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Biomarqueurs moléculaires pour la prédiction de la réponse aux inhibiteurs de la tyrosine kinase dans le cancer du poumon
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US9314450B2 (en) 2011-01-11 2016-04-19 Dimerix Bioscience Pty Ltd. Combination therapy
WO2012109329A2 (fr) 2011-02-08 2012-08-16 Children's Medical Center Corporation Méthodes de traitement d'un mélanome
EP2492688A1 (fr) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Biomarqueurs moléculaires pour la prédiction de la réponse à un traitement antitumoral dans le cancer du poumon
SI2683244T1 (sl) 2011-03-08 2017-05-31 3-V Biosciences, Inc. Heterociklični modulatorji sinteze lipidov
KR20140145947A (ko) 2011-03-16 2014-12-24 암젠 인크 Nav1.3과 nav1.7의 유효한 선별적 저해제
WO2012134975A1 (fr) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Méthodes et compositions utilisant des protéines de fusion immunogènes
WO2012130193A1 (fr) 2011-03-31 2012-10-04 Zentiva, K.S. Complexes solubles non covalents de tériparatide contenant des polysaccharides et forme pharmaceutique de tériparatide pour administration orale
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
WO2012151525A1 (fr) 2011-05-04 2012-11-08 Rhizen Pharmaceuticals Sa Nouveaux composés en tant que modulateurs de protéines kinases
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
ES2653918T3 (es) 2011-08-31 2018-02-09 St. Jude Children's Research Hospital Métodos y composiciones para detectar el nivel de actividad de exocitosis lisosómica y métodos de uso
CN103889993B (zh) 2011-09-19 2017-05-31 吉奇亚公司 修饰的肌酸化合物
EP2766483B1 (fr) 2011-10-10 2022-03-23 The Hospital For Sick Children Méthodes et compositions de dépistage et de traitement de troubles du développement
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
SI3091029T1 (sl) 2011-10-31 2023-03-31 F. Hoffmann - La Roche Ag Pripravki protiteles proti IL13
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
WO2013120018A1 (fr) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Méthodes et compositions permettant de rechercher et de traiter des troubles du développement
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
EA201691327A1 (ru) 2012-03-05 2017-03-31 Джилид Калистога Ллс Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
BR112014024251A8 (pt) 2012-03-30 2018-01-23 Rhizen Pharmaceuticals S A novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
WO2013162772A2 (fr) 2012-04-24 2013-10-31 University Of Miami Défense par la perforine-2 contre des pathogènes invasifs et polyrésistants
EP2662079A1 (fr) 2012-05-10 2013-11-13 Ordway Research Institute, Inc. Utilisations de formulations d'antagonistes d'hormone thyroïdienne et leurs formes nanoparticulaires associées pour augmenter la chimio-sensibilité et radio-sensibilité dans les cellules cancéreuses ou tumorales
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
EP2900835A4 (fr) 2012-09-27 2016-05-11 Population Diagnotics Inc Procédés et compositions de dépistage et de traitement de troubles du développement
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
EP3545978B1 (fr) 2013-01-14 2021-09-08 Molecular Insight Pharmaceuticals, Inc. Produits radiopharmaceutiques à base de triazine et agents de radioimagerie
US20140255403A1 (en) 2013-03-06 2014-09-11 Hadasit Medical Research Services & Development Ltd. Oral composition comprising a tnf antagonist and use thereof
EP2970408B1 (fr) 2013-03-12 2018-01-10 Amgen Inc. Inhibiteurs sélectifs et puissants de nav1.7
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP2968373A2 (fr) 2013-03-15 2016-01-20 Gencia Corporation Compositions et méthodes de traitement d'affections qui touchent l'épiderme
WO2014144763A2 (fr) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center Anticorps anti-gd2 à haute affinité
CA2906817C (fr) 2013-03-15 2022-01-18 Mannkind Corporation Compositions de dicetopiperazine microcristallines et procedes
WO2014144003A1 (fr) 2013-03-15 2014-09-18 Mannkind Corp. Formation de bis-3,6-(4-aminobutyl)-2,5-dicétopipérazine n-protégée par un amino ester alpha-n-protégé cyclique
KR102424765B1 (ko) 2013-04-12 2022-07-22 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
US10647983B2 (en) 2013-09-04 2020-05-12 Cold Spring Harbor Laboratory Reducing nonsense-mediated mRNA decay
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
CA2934251C (fr) 2013-12-20 2024-01-02 3-V Biosciences, Inc. Combinaison de modulateurs heterocycliques de synthese des lipides et medicaments chimiotherapeutiques dans le traitement du cancer
EP3083623A1 (fr) 2013-12-20 2016-10-26 Gilead Calistoga LLC Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
NZ721780A (en) 2014-01-07 2022-01-28 Sagimet Biosciences Inc Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
WO2015149016A2 (fr) 2014-03-28 2015-10-01 University Of Washington Through Its Center For Commercialization Vaccins contre le cancer du sein et des ovaires
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2015179654A1 (fr) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinction d'anticorps anti-b7-h1 agonistes et antagonistes
CA2951391C (fr) 2014-06-10 2021-11-02 Amgen Inc. Polypeptides d'apeline
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
EP3171896A4 (fr) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
WO2018140026A1 (fr) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Molécules bispécifiques de liaison à her2 et cd3
GB2558326B (en) 2014-09-05 2021-01-20 Population Bio Inc Methods and compositions for inhibiting and treating neurological conditions
WO2016054240A1 (fr) 2014-09-30 2016-04-07 Sean Dalziel Combinaisons à dose fixe pour le traitement de maladies virales
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2964480A1 (fr) 2014-10-31 2016-05-06 Whole Biome Inc. Procedes et compositions se rapportant a un traitement microbien et au diagnostic de troubles
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
WO2016149271A1 (fr) 2015-03-19 2016-09-22 3-V Biosciences, Inc. Modulateurs hétérocycliques de synthèse de lipides
WO2017075045A2 (fr) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Anticorps anti-b7-h1
WO2017105990A1 (fr) 2015-12-14 2017-06-22 Massachusetts Institute Of Technology Microorganismes à encapsulation en polymères mucoadhésifs sensibles au ph
US10973748B2 (en) 2016-04-21 2021-04-13 Versitech Limited Compositions and methods for lightening skin and reducing hyperpigmentation
US10845367B2 (en) 2016-05-04 2020-11-24 Abilita Bio, Inc. Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents
AU2017279536A1 (en) 2016-06-07 2018-12-20 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists
JP2019528044A (ja) 2016-07-15 2019-10-10 ポセイダ セラピューティクス， インコーポレイテッド Ｍｕｃ１に特異的なキメラ抗原受容体（ｃａｒｓ）およびその使用方法
BR112019000683A2 (pt) 2016-07-15 2019-04-24 Poseida Therapeutics Inc receptores de antígeno quiméricos e métodos para uso
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
EP3675882A4 (fr) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. Methodes et compositions pour le traitement de troubles associés au microbiome
EP3697417A1 (fr) 2017-10-17 2020-08-26 Rhizen Pharmaceuticals S.A. Modulateurs de canal crac pour le traitement du cancer de l' sophage
WO2019082124A1 (fr) 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa Composition et procédé pour le traitement du lymphome diffus à grandes cellules b
JP2021501160A (ja) 2017-10-30 2021-01-14 ルヒゼン ファーマスティカルズ エスエー 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター
WO2019111185A1 (fr) 2017-12-06 2019-06-13 Rhizen Pharmaceuticals Sa Composition et méthode de traitement d'un lymphome t périphérique et d'un lymphome t cutané
MX2020006689A (es) 2017-12-20 2020-11-06 Poseida Therapeutics Inc Composiciones de vcar y metodos de uso.
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
WO2020001657A1 (fr) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions et méthodes de traitement de la neuropathie optique héréditaire de leber
WO2020023507A1 (fr) * 2018-07-23 2020-01-30 Cornell University Cristaux d'acides aminés polyédriques fluorescents naturels pour le piégeage efficace et l'administration systémique de petites molécules hydrophobes
ES2935891T3 (es) 2018-08-08 2023-03-13 Pml Screening Llc Métodos para evaluar el riesgo de desarrollar leucoencefalopatía multifocal progresiva causada por virus de John Cunningham mediante pruebas genéticas
EP3840785A4 (fr) 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company Compositions et méthodes de traitement de la neuropathie optique héréditaire de leber
KR20210069665A (ko) 2018-09-27 2021-06-11 포스포감, 인크. 동종이계 감마/델타-t 세포의 확장 및 사용을 위한 방법 및 조성물
JP2022513507A (ja) 2018-12-20 2022-02-08 ポセイダ セラピューティクス，インコーポレイティド ナノトランスポゾン組成物および使用方法
MX2021008537A (es) 2019-01-15 2021-11-12 Janssen Biotech Inc Composiciones de anticuerpos anti-tnf y métodos para el tratamiento de la artritis idiopática juvenil.
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
JP2022526881A (ja) 2019-03-14 2022-05-27 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
MA55282A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
US20220153829A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
CA3133652A1 (fr) 2019-04-01 2020-10-08 Genentech, Inc. Compositions et procedes de stabilisation de formulations contenant des proteines
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
CA3142580A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et methodes pour le traitement de la spondylarthrite ankylosante active
WO2020245676A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
CA3149892A1 (fr) 2019-09-05 2021-03-11 Eric M. Ostertag Compositions de cellules allogeniques et procedes d'utilisation
AU2020370110A1 (en) 2019-10-21 2022-05-26 Rhizen Pharmaceuticals Ag Compositions comprising a DHODH inhibitor for the treatment of acute myeloid leukemia
CN113025633A (zh) 2019-12-09 2021-06-25 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
US20230079955A1 (en) 2019-12-20 2023-03-16 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
KR20220149588A (ko) 2020-03-04 2022-11-08 포세이다 테라퓨틱스, 인크. 대사성 간 장애의 치료를 위한 조성물 및 방법
EP4118107A1 (fr) 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Récepteurs stimulateurs chimériques et procédés d'utilisation dans l'activation et la différenciation de lymphocytes t
KR20230011295A (ko) 2020-04-14 2023-01-20 포세이다 테라퓨틱스, 인크. 암 치료에 사용하기 위한 조성물 및 방법
WO2021214587A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections virales
WO2021214588A1 (fr) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Agent anti-tnf alpha pour traiter des infections à coronavirus
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
EP4298205A1 (fr) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Cellules souches pluripotentes induites génétiquement modifiées et leurs procédés d'utilisation
US20240182921A1 (en) 2021-03-04 2024-06-06 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
WO2023280157A1 (fr) 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 Construction et utilisation d'anticorps anti-vegf dans un système d'expression in vivo
AU2022306144A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
EP4370545A1 (fr) 2021-07-12 2024-05-22 Genentech, Inc. Structures pour réduire la liaison anticorps-lipase
BR112024002305A2 (pt) 2021-08-06 2024-04-30 Wuhan Neurophth Biotechnology Ltd Company Composição e método para tratamento de neuropatia óptica hereditária de leber causada por mutação de nd4
WO2023017537A1 (fr) 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Composition peptidique orale perméable au tractus gastro-intestinal à base d'huile algale
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
WO2023164573A1 (fr) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Cellules modifiées et leurs procédés d'utilisation
WO2024036273A1 (fr) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Compositions chimériques de corécepteurs cd8-alpha et procédés d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576758A (en) * 1966-10-17 1971-04-27 Ncr Co Treatment of polypeptide-containing hydrophilic polymeric capsule wall material with uranium and vanadium compounds
US3962416A (en) * 1971-01-25 1976-06-08 Sol Katzen Preserved nutrients and products
CA1045977A (fr) * 1973-05-17 1979-01-09 Arthur D. Little Implant biodegradable pour la dispensation de medicaments et procede de preparation et d'utilisation
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4217370A (en) * 1977-08-25 1980-08-12 Blue Wing Corporation Lipid-containing feed supplements and foodstuffs
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4483807A (en) * 1981-01-27 1984-11-20 Japan Atomic Energy Research Institute Process for producing a slow release composite
JPS583511A (ja) * 1981-06-25 1983-01-10 住友電気工業株式会社 ケ−ブル接続部の防水方法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
CA1196862A (fr) * 1983-06-01 1985-11-19 Anthony M.F. Sun Microencapsulement de cellules et de tissus vivants
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
FR2565102B1 (fr) * 1984-06-05 1987-03-20 Paris Sud Universite Microcapsules biodegradables a base de serumalbumine, leur preparation et leur application a la liberation in situ de medicuments
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
GB2217201A (en) 1989-10-25
JP2876058B2 (ja) 1999-03-31
NL8720442A (nl) 1989-04-03
US4925673A (en) 1990-05-15
EP0318512B1 (fr) 1998-06-17
EP0318512A1 (fr) 1989-06-07
NO881664D0 (no) 1988-04-18
GB2217201B (en) 1991-01-23
WO1988001213A1 (fr) 1988-02-25
NO178055B (no) 1995-10-09
NO881664L (no) 1988-04-18
NO178055C (no) 1996-01-17
CA1323305C (fr) 1993-10-19
EP0318512A4 (fr) 1989-06-14
SE8900542D0 (sv) 1989-02-16
EP0545913B1 (fr) 1999-02-24
GB8830377D0 (en) 1989-03-08
EP0545913A1 (fr) 1993-06-09
AU610083B2 (en) 1991-05-16
AU7875287A (en) 1988-03-08
CH671155A5 (fr) 1989-08-15
SE8900542L (sv) 1989-02-16
JPH02500669A (ja) 1990-03-08

Similar Documents

Publication Publication Date Title
SE502324C2 (sv) Administreringssystem för farmakologiskt aktiva medel som är inkapslade i skyddande proteinoidmikrosfärer
USRE35862E (en) Delivery systems for pharmacological agents encapsulated with proteinoids
Ramadas et al. Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats
Touitou et al. Targeted enteral delivery of insulin to rats
US4976968A (en) Anhydrous delivery systems for pharmacological agents
CA2415414C (fr) Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
JP4713798B2 (ja) ペプチドおよびタンパク質の薬学的因子の精製および安定化
Kostanski et al. A novel in vitro release technique for peptide-containing biodegradable microspheres
JPH07506818A (ja) 自己アセンブリ性ジケトピペラジン薬物送達系
US8859004B2 (en) pH-sensitive nanoparticles for oral insulin delivery
CA2547531A1 (fr) Articles polymeres flottants pour l'administration d'agents therapeutiques au systeme nerveux central
Boehnke et al. Stabilization of glucagon by trehalose glycopolymer nanogels
JPH10203964A (ja) 難吸収性薬剤の経口生物学的利用能を改善する新しい調剤
EP0001197B1 (fr) Produits de couplage de la cytidine-diphosphocholine et de composés aminés, procédé d'obtention et application pharmaceutique et analytique
Kassir et al. Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies
CA2621641A1 (fr) Formulation de nanoparticules sensibles au ph pour l'administration orale de proteines/peptides
CN102525876A (zh) 阿司匹林固体分散体、其制备方法、药物组合物和用途
KR950009089B1 (ko) 약리학적 제제의 전달 시스템
CN101721687B (zh) 胰岛素-羟基磷灰石纳米复合物及其制备方法和应用
DE3790487C2 (de) Mikroverkapselung für pharmakologische Mittel
DE3745075C2 (de) Mikroverkapselung für pharmakologische Mittel
JP2021528498A (ja) 経口投与用生物学的ポリマーの製剤
BR112020000599A2 (pt) maltodextrinas reticuladas para a liberação oral de ativos biológicos
PT86571B (pt) Metodo para a microencapsulacao de agentes farmacologicos e processo para a preparacao de composicoes farmaceuticas que contem esses agentes
Hauss et al. The influence of concentration of two salicylate derivatives on rectal insulin absorption enhancement

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8900542-5

Format of ref document f/p: F